MediWound Ltd. announced the signing of an agreement granting COVALEO SA de CV exclusive rights to market and distribute NexoBrid® in Mexico for the treatment of severe burns. Severe burns are primarily treated at approximately 20 hospitals and burn centers in Mexico. NexoBrid is an easy-to-use, topically-applied pharmaceutical product that removes dead or damaged tissue, known as eschar, in approximately four hours without harming the surrounding healthy tissue.

This innovative treatment for severe burns has received marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, and was commercially launched in Europe and Israel. Sales of NexoBrid in Mexico will commence after receipt of local regulatory approval, which will be filed with the Mexican regulatory authorities by COVALEO and is expected to be granted within a year or possibly longer. In addition to this agreement in Mexico, MediWound has executed exclusive distribution agreements for NexoBrid to treat severe burns in Argentina, Russia and South Korea.